Praxis precision medicines provides corporate update and reports first quarter 2024 financial results

Plans to initiate two efficacy studies investigating prax-628 in focal onset seizures in the second half of 2024 and first half of 2025, respectively

PRAX Ratings Summary

PRAX Quant Ranking